Leiden University Scholarly Publications

Your Search

Enabled Filters

  • (-) = Arendt, C.

Search results

  • RSS Feed
(1 - 3 of 3)
Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naive patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study
Emery, P.; Bingham, C.O.; Burmester, G.R.; Bykerk, V.P.; Furst, D.E.; Mariette, X.; ... ; Weinblatt, M.E. 2017
Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naive patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study
Article / Letter to editor
open access
Response to: "Let's stop fooling ourselves. In RA, only ACR/EULAR criteria define remission and equate with absence of disease!' by Boers
Emery, P.; Bingham, C.O.; Burmester, G.R.; Bykerk, V.P.; Furst, D.E.; Mariette, X.; ... ; Weinblatt, M.E. 2016
Response to: "Let's stop fooling ourselves. In RA, only ACR/EULAR criteria define remission and equate with absence of disease!' by Boers
Article / Letter to editor
metadata only
Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients
Smolen, J.S.; Vollenhoven, R. van; Kavanaugh, A.; Strand, V.; Vencovsky, J.; Schiff, M.; ... ; Heijde, D. van der 2015
Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients
Article / Letter to editor
metadata only